Nektar Therapeutics Statistics
Nektar Therapeutics (NKTR) Stock Statistics & Valuation Metrics
Total Valuation
Nektar Therapeutics has a market cap or net worth of CHF 1.06B. The enterprise value is CHF 1.76B.
- Market Cap
- CHF 1.06B
- Enterprise Value
- CHF 1.76B
Share Statistics
Nektar Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- ―
- Owned by Insiders
- 0.46%
- Owned by Institutions
- 48.07%
Financial Efficiency
Nektar Therapeutics’s return on equity (ROE) is -1.83 and return on invested capital (ROIC) is -52.82%.
- Return on Equity (ROE)
- -1.83
- Return on Assets (ROA)
- -0.59
- Return on Invested Capital (ROIC)
- -52.82%
- Return on Capital Employed (ROCE)
- -0.58
- Revenue Per Employee
- 876.70K
- Profits Per Employee
- -2.60M
- Employee Count
- 63
- Asset Turnover
- 0.20
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Nektar Therapeutics is -5.64. Nektar Therapeutics’s PEG ratio is -0.59.
- PE Ratio
- -5.64
- PS Ratio
- 19.85
- PB Ratio
- 1.38
- Price to FCF
- -4.63
- Price to Operating Cash Flow
- -5.34
- PEG Ratio
- -0.59
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 55.23M and earned -164.08M in profits. Earnings per share was -9.73.
- Revenue
- 55.23M
- Gross Profit
- 55.23M
- Operating Income
- -130.77M
- Pretax Income
- -164.21M
- Net Income
- -164.08M
- EBITDA
- -137.00M
- Earnings Per Share (EPS)
- -9.73
Cash Flow
In the last 12 months, operating cash flow was -233.79M and capital expenditures -262,000, giving a free cash flow of -234.05M billion.
- Operating Cash Flow
- -233.79M
- Free Cash Flow
- -234.05M
- Free Cash Flow per Share
- -7.08
Dividends & Yields
Nektar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -21.46%
- Earnings Yield
- -12.50%
Important Dates
Nektar Therapeutics upcoming earnings date is Nov 12, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Nektar Therapeutics as a current ratio of 4.97, with Debt / Equity ratio of 165.76%
- Current Ratio
- 4.97
- Quick Ratio
- 4.97
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- -0.98
- Interest Coverage Ratio
- -4.99
Taxes
In the past 12 months, Nektar Therapeutics has paid -138.00K in taxes.
- Income Tax
- -138.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Nektar Therapeutics EV to EBITDA ratio is -8.85, with an EV/FCF ratio of -5.07.
- EV to Sales
- 21.75
- EV to EBITDA
- -8.85
- EV to Free Cash Flow
- -5.07
- EV to Operating Cash Flow
- -5.08
Balance Sheet
Nektar Therapeutics has CHF 684.34M in cash and marketable securities with CHF 135.93M in debt, giving a net cash position of CHF 548.41M billion.
- Cash & Marketable Securities
- CHF 684.34M
- Total Debt
- CHF 135.93M
- Net Cash
- CHF 548.41M
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- CHF 27.32
Margins
Gross margin is 99.36%, with operating margin of -240.38%, and net profit margin of -287.84%.
- Gross Margin
- 99.36%
- Operating Margin
- -240.38%
- Pretax Margin
- -287.13%
- Net Profit Margin
- -287.84%
- EBITDA Margin
- -245.90%
- EBIT Margin
- -247.17%
Analyst Forecast
The average price target for Nektar Therapeutics is CHF 108.56, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CHF 108.56
- Price Target Upside
- ―
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 14
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- ―
